Loophole in Trump GLP-1 pricing deal with Lilly and Novo Nordisk, STAT reports

STAT reported on June 30 that the Trump administration's GLP-1 pricing deal with Eli Lilly and Novo Nordisk contains a loophole: the most-favored-nation commitments left the two companies room to keep list prices high in sales channels the agreement does not cover, complicating claims that American prices have come down across the board ^[1].

The bargain, announced in November 2025, was built on a simple premise — lower prices in exchange for higher sales volume ^[1]. Eli Lilly and Novo Nordisk agreed to a monthly $245 price for GLP-1 medicines in Medicare and Medicaid. That price was supposed to apply to all GLP-1s, including obesity drugs, which Medicare had not covered before the deal ^[1]. The administration described the agreement as bringing most-favored-nation pricing to American patients ^[1].

But the $245 price came with a condition. According to STAT, it depended on private Medicare insurers agreeing to cover the drugs for all uses, with a $50 copay ^[1]. The administration did not publicly mention that condition when it announced the deal, and Novo Nordisk and Lilly recently confirmed it to STAT ^[1].

STAT reported that the companies ended up with higher sales volume without the lower prices in some cases ^[1]. Because the discounted price hinges on decisions by private Medicare plans rather than on a change in the manufacturers' list prices, its reach is limited to the parts of the market where those conditions are met ^[1]. STAT called that gap the loophole in the deal ^[1].

The report did not say which channels fall outside the agreement, what list prices are in those channels, or how many private Medicare plans have agreed to the all-uses coverage. Those details have not been disclosed.

Why it matters for patients

The $245 monthly figure applies to Medicare and Medicaid under conditions set by the deal, not to every purchase of a GLP-1 ^[1]. For people in other types of coverage, the report does not describe a change in what they pay, and STAT's analysis found the companies kept room to hold list prices high in channels the agreement does not cover ^[1].

The practical question for Medicare beneficiaries is whether their private plan agrees to cover the drugs for all uses with the $50 copay, because the $245 price depends on that ^[1]. Before the deal, Medicare did not cover GLP-1 medicines for obesity at all, so coverage for weight loss is new and tied to plan decisions ^[1].

List prices also matter to people who pay cash or whose cost-sharing is calculated from a list price rather than a negotiated rate. STAT reported that the prospect of lower prices across the board is more complicated than the deal's headline number suggests ^[1].

What happens next

STAT reported that Lilly and Novo Nordisk confirmed the coverage condition to the publication, but no schedule has been reported for when private Medicare insurers will decide on all-uses coverage, or for when the $245 price will apply broadly ^[1]. It also has not been reported whether the two companies plan to change list prices in the channels the deal does not cover, or how many Medicare plans have signed on so far ^[1].